- Home
- TIRX vs APRE Comparison
TIRX vs APRE Comparison
Compare TIRX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIRX
- APRE
- Stock Information
- Founded
- TIRX 2010
- APRE 2006
- Country
- TIRX China
- APRE United States
- Employees
- TIRX N/A
- APRE N/A
- Industry
- TIRX Specialty Insurers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TIRX Finance
- APRE Health Care
- Exchange
- TIRX Nasdaq
- APRE Nasdaq
- Market Cap
- TIRX 12.0M
- APRE 10.0M
- IPO Year
- TIRX 2021
- APRE 2019
- Fundamental
- Price
- TIRX $1.15
- APRE $1.68
- Analyst Decision
- TIRX
- APRE Strong Buy
- Analyst Count
- TIRX 0
- APRE 2
- Target Price
- TIRX N/A
- APRE $15.50
- AVG Volume (30 Days)
- TIRX 68.6K
- APRE 63.8K
- Earning Date
- TIRX 08-15-2025
- APRE 08-11-2025
- Dividend Yield
- TIRX N/A
- APRE N/A
- EPS Growth
- TIRX N/A
- APRE N/A
- EPS
- TIRX N/A
- APRE N/A
- Revenue
- TIRX $3,219,336.00
- APRE $1,284,475.00
- Revenue This Year
- TIRX N/A
- APRE N/A
- Revenue Next Year
- TIRX N/A
- APRE N/A
- P/E Ratio
- TIRX N/A
- APRE N/A
- Revenue Growth
- TIRX 158.74
- APRE 33.27
- 52 Week Low
- TIRX $1.07
- APRE $1.41
- 52 Week High
- TIRX $4.15
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- TIRX 37.55
- APRE 50.08
- Support Level
- TIRX $1.11
- APRE $1.60
- Resistance Level
- TIRX $1.18
- APRE $1.78
- Average True Range (ATR)
- TIRX 0.07
- APRE 0.12
- MACD
- TIRX 0.00
- APRE -0.00
- Stochastic Oscillator
- TIRX 8.57
- APRE 35.23
About TIRX TIAN RUIXIANG Holdings Ltd
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.